Genmab Files Annual Report with the U.S. Securities and Exchange Commission
February 14, 2024 14:09 ET
|
Genmab A/S
Media Release COPENHAGEN, Denmark; February 14, 2024 Genmab filed Form 20-F for the financial year 2023 with the U.S. SEC Genmab A/S (Nasdaq: GMAB) announced today that it has filed its Annual...
Genmab Announces Initiation of Share Buy-Back Program
February 14, 2024 11:41 ET
|
Genmab A/S
Company Announcement Repurchase of up to 190,000 shares Honoring commitments under our Restricted Stock Unit program Completion expected on March 15, 2024 COPENHAGEN, Denmark; February 14, 2024 –...
Genmab Publishes 2023 Annual Report
February 14, 2024 11:02 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; February 14, 2024 – Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2023. Below is a summary of business progress in...
Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer
February 02, 2024 06:45 ET
|
Genmab A/S
Media ReleaseCOPENHAGEN, Denmark; February 2, 2024 Validation is supported by data from Phase 3 innovaTV 301 trial Genmab A/S (Nasdaq: GMAB) and Pfizer, Inc. (NYSE PFE) today announced that the...
Grant of Restricted Stock Units and Warrants to Employees in Genmab
January 25, 2024 14:22 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; January 25, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 5,281 restricted stock units and 5,468 warrants to employees of...
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2023
January 23, 2024 06:24 ET
|
Genmab A/S
Company Announcement Net sales of DARZALEX® in 2023 totaled USD 9,744 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; January...
Genmab Announces Decision in Arbitration Appeal under License Agreement with Janssen
January 22, 2024 18:40 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; January 23, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that the appeal arbitrator in its second arbitration arising under its license agreement with...
TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer
January 09, 2024 06:45 ET
|
Genmab A/S
Media Release COPENHAGEN, Denmark; January 9, 2024 TIVDAK sBLA accepted for priority review, FDA action date is May 9, 2024Submission based on positive results from global phase 3 innovaTV 301...
Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
January 03, 2024 00:55 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; January 3, 2024 – Genmab A/S (Nasdaq: GMAB) – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523,...
Genmab to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024 09:52 ET
|
Genmab A/S
Media Release COPENHAGEN, Denmark; January 2, 2024 Genmab A/S (Nasdaq: GMAB) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the 42nd Annual J.P. Morgan...